

Walter Curran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11875826/publications.pdf>

Version: 2024-02-01

21
papers

7,270
citations

361045

20
h-index

713013

21
g-index

22
all docs

22
docs citations

22
times ranked

6976
citing authors

#	ARTICLE	IF	CITATIONS
1	Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 187-199.	5.1	1,625
2	Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402. <i>Journal of Clinical Oncology</i> , 2013, 31, 337-343.	0.8	968
3	A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 510-514.	0.4	907
4	Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <i>Journal of Clinical Oncology</i> , 2006, 24, 2707-2714.	0.8	678
5	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 157-165.	0.8	523
6	Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 1001-1006.	0.4	502
7	Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. <i>Journal of Clinical Oncology</i> , 2006, 24, 5711-5715.	0.8	500
8	Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases. <i>Journal of Clinical Oncology</i> , 2003, 21, 2529-2536.	0.8	438
9	A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the radiation therapy oncology group (RTOG) 9104. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 571-574.	0.4	317
10	Lead-In Phase to Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation for Patients With Brain Metastases: Centralized Assessment of Magnetic Resonance Imaging, Neurocognitive, and Neurologic End Points. <i>Journal of Clinical Oncology</i> , 2002, 20, 3445-3453.	0.8	141
11	Spinal cord gliomas: A multi-institutional retrospective analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1060-1071.	0.4	120
12	Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. <i>International Journal of Radiation Oncology Biology Physics</i> , 1993, 26, 653-657.	0.4	107
13	RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database. <i>Journal of Clinical Oncology</i> , 2003, 21, 2364-2371.	0.8	101
14	Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 123, 103-111.	1.4	73
15	Current Dosing Paradigm for Stereotactic Radiosurgery Alone After Surgical Resection of Brain Metastases Needs to Be Optimized for Improved Local Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e61-e66.	0.4	72
16	Cognition and Quality of Life After Chemotherapy Plus Radiotherapy (RT) vs. RT for Pure and Mixed Anaplastic Oligodendrogliomas: Radiation Therapy Oncology Group Trial 9402. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 662-669.	0.4	47
17	Six degrees of freedom CBCT-based positioning for intracranial targets treated with frameless stereotactic radiosurgery. <i>Journal of Applied Clinical Medical Physics</i> , 2012, 13, 215-225.	0.8	44
18	Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. <i>Cancers</i> , 2021, 13, 6193.	1.7	39

#	ARTICLE	IF	CITATIONS
19	Results of the Phase I Dose-Escalating Study of Motexafin Gadolinium With Standard Radiotherapy in Patients With Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 831-838.	0.4	38
20	Prognostic Factors and Survival in Patients With Spinal Cord Gliomas After Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 344-351.	0.6	28
21	In Reply to Drs. Nieder and Molls. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1619.	0.4	0